|Main uses||Increased intraocular pressure|
|Side effects||Eye pain, eye redness|
|US NLM||Latanoprostene bunod|
|Chemical and physical data|
|Molar mass||507.624 g·mol−1|
|3D model (JSmol)|
Common side effects include eye pain and eye redness. Other side effects may include bacterial keratitis, macular edema, darkening of the skin around the eye, and eyelash changes. It is a prostaglandin which increases outflow through the trabecular meshwork and uveoscleral pathway.
Latanoprostene bunod was approved for medical use in the United States in 2017. In the United States it costs about 230 USD for a 2.5 ml bottle as of 2021. As of 2021 it is not commercially available in the United Kingdom or Europe.
- "Latanoprostene Bunod Monograph for Professionals". Drugs.com. Retrieved 21 November 2021.
- Hoy SM (May 2018). "Latanoprostene Bunod Ophthalmic Solution 0.024%: A Review in Open-Angle Glaucoma and Ocular Hypertension". Drugs. 78 (7): 773–780. doi:10.1007/s40265-018-0914-6. PMC 5976683. PMID 29761382.
- "Vyzulta Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 21 November 2021.
- "Latanoprostene bunod". SPS - Specialist Pharmacy Service. 25 January 2016. Retrieved 21 November 2021.